<div id="readability-page-1"><p>BTIG analyst Mark Massaro reiterated a Buy rating on Guardant Health on May 8 and set a price target of $145.00. The company’s shares closed last Friday at $95.70.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Massaro covers the Healthcare sector, focusing on stocks such as Cerus, SOPHiA GENETICS, and NeoGenomics. According to TipRanks, Massaro has an average return of <span>-4.7%</span> and a 31.91% success rate on recommended stocks. </p> <p>In addition to BTIG, Guardant Health also received a Buy from TD Cowen’s Daniel Brennan in a report issued on May 8. However, on the same day, Evercore ISI maintained a Hold rating on Guardant Health (NASDAQ: GH).</p></div>

<p>BTIG analyst Mark Massaro has reaffirmed a Buy rating on Guardant Health (GH) with a price target of $145.00, while the shares closed at $95.70. On the same day, TD Cowen's Daniel Brennan also issued a Buy rating, but Evercore ISI maintained a Hold rating. Massaro has an average return of -4.7% and a 31.91% success rate on his stock recommendations.</p>

Tip Ranks

Guardant Health

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares US Healthcare Providers

Ark Genomic Revolution ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

iShares Genomics Immunology and Healthcare ETF

Cerus

Sophia Genetics SA

Neogenomics

BTIG Reaffirms Their Buy Rating on Guardant Health (GH)